Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of romidepsin + CHOP versus CHOP in previously untreated peripheral T-cell lymphoma
2012-001580-68Phase 3Completed
- Sponsor
- LYSARC
- Start
- Jan 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of romidepsin in peripheral T-cell lymphoma (PTCL) (2 arms), sponsored by LYSARC. Primary endpoint: Progression-free survival. Started Jan 2013; status: completed.
02
Drugs
romidepsin
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on 2012-001580-68.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001580-68.